CDB-2914
Sponsors
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Pittsburgh, HRA Pharma, Population Council
Conditions
ContraceptionEmergency ContraceptionHealthyLeiomyomaUrogenital Abnormalities
Early Phase 1
Phase 1
Phase 2
Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist
CompletedNCT00044876
Start: 2002-09-02End: 2015-10-01Updated: 2019-12-17
Efficacy Trial of CDB 2914 for Emergency Contraception
CompletedNCT00271583
Start: 1999-09-30End: 2001-09-30Updated: 2007-12-17
Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914
CompletedNCT00791297
Start: 2008-10-31End: 2014-09-30Updated: 2017-08-15